Abstract
Objective T helper cells develop into discrete Th1, Th2 or Th17 lineages that selectively express IFNγ, IL-4/IL-5/IL-13, or IL-17, respectively and actively silence signature cytokines expressed by opposing lineages. Our objective was to compare Th1, Th2 and Th17 polarization in cell culture models using JIA patient samples.
Methods Peripheral blood mononuclear cells were isolated from JIA or healthy prepubescent children. T cell naïve and memory phenotypes were assessed by flow cytometry. T cell proliferation was measured using a fluorescence-based assay. Th cell cultures were generated in vitro and IFNγ, IL-17, and TNFα measured by ELISA and flow cytometry.
Results JIA Th1 cells produced increased IFNγ and inappropriately produced IL-17. JIA Th17 cells produced increased IL-17. JIA Th1 cell cultures develop dual producers of IFNγ and IL-17, which are Th1.17 cells. JIA Th1 cultures expressed elevated levels of both T-bet and RORγT. RNA sequencing confirmed activation of immune responses and inappropriate activation of IL-17 signaling pathways in Th1 cultures. A subset of JIA patient samples was disproportionally responsible for the enhanced IFNγ and IL-17 phenotype and Th1.17 phenotype.
Conclusions This study reveals that JIA patient uncommitted T cell precursors, but not healthy children, inappropriately develop into inflammatory effector Th1.17 and Th17 cells under Th1 polarizing conditions.
Rheumatology key messages
Th1 differentiation of JIA PBMCs generates high IFNγ, IL-17, and dual IFNγ-IL-17 producing cells.
JIA Th1 differentiation increases master transcription factor expression for Tbet and RORγT.
Enhanced JIA Th1 IFNγ and IL-17 production occurs in a subset of JIA patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institutes of Health [R01AI044924 to T.M.A], [P30AR070549 and P01AR048929 to S.D.T.], [K08HL153789 and IK2BX005376 to D.M.P.], [K12HD087023 to Research Scholar A.E.P.]. The VUMC Flow Cytometry Shared Resource was supported by the National Institutes of Health [P30CA68485 to the Vanderbilt Ingram Cancer Center], [DK058404 to the Vanderbilt Digestive Disease Research Center]. The Cincinnati Genomic Control Cohort was supported by the Cincinnati Childrens Research Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research is approved by the Vanderbilt University Medical Center IRB and the Cincinnati Children's Hospital Medical Center IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data included in this study are available upon request by contacting the corresponding author. The sequences presented in this article have been submitted to the National Center for Biotechnology Information Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/).